Amicus Therapeutics (FRA:AM6) 3-Year Book Growth Rate : -20.70% (As of Dec. 2023)

View and export this data going back to 2007. Start your Free Trial

What is Amicus Therapeutics 3-Year Book Growth Rate?

Amicus Therapeutics's Book Value per Share for the quarter that ended in Dec. 2023 was €0.50.

During the past 12 months, Amicus Therapeutics's average Book Value per Share Growth Rate was 24.70% per year. During the past 3 years, the average Book Value per Share Growth Rate was -20.70% per year. During the past 5 years, the average Book Value per Share Growth Rate was -25.60% per year. During the past 10 years, the average Book Value per Share Growth Rate was -9.00% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Book Value per Share growth rate.

During the past 13 years, the highest 3-Year average Book Value per Share Growth Rate of Amicus Therapeutics was 50.70% per year. The lowest was -38.30% per year. And the median was -17.50% per year.

Competitive Comparison of Amicus Therapeutics's 3-Year Book Growth Rate

For the Biotechnology subindustry, Amicus Therapeutics's 3-Year Book Growth Rate, along with its competitors' market caps and 3-Year Book Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Amicus Therapeutics's 3-Year Book Growth Rate Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Amicus Therapeutics's 3-Year Book Growth Rate distribution charts can be found below:

* The bar in red indicates where Amicus Therapeutics's 3-Year Book Growth Rate falls into.

Amicus Therapeutics 3-Year Book Growth Rate Calculation

This is the 3-year average growth rate of Book Value per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Book Value per Share growth rate.

Amicus Therapeutics (FRA:AM6) 3-Year Book Growth Rate Explanation

Book Value per Share is the ratio of equity available to common shareholders divided by the shares outstanding. Book value per share effectively indicates a firm's net asset value on a per-share basis. It can be used by investors to gauge whether a stock price is undervalued by comparing it to the firm's market value per share. Theoretically, it is what the shareholders will receive if the company is liquidated.

Amicus Therapeutics 3-Year Book Growth Rate Related Terms

Thank you for viewing the detailed overview of Amicus Therapeutics's 3-Year Book Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.

Amicus Therapeutics (FRA:AM6) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Amicus Therapeutics Inc (FRA:AM6) » Definitions » 3-Year Book Growth Rate

Comparable Companies

Traded in Other Exchanges

FOLD:USA AM6:Germany

Address

3675 Market Street, Philadelphia, PA, USA, 19104

Website

https://www.amicusrx.com

Amicus Therapeutics Inc is a biotechnology company focused on discovering, developing and delivering medicines for people living with rare metabolic diseases. The company is engaged in developing a pipeline of medicines for rare metabolic diseases, including a rare disease gene therapy portfolio. It has a portfolio of product opportunities, including oral precision medicine for people living with Fabry disease who have amenable genetic variants; a clinical-stage, treatment paradigm for Pompe disease, and a rare disease gene therapy portfolio. The company has one segment focused on the discovery, development, and commercialization of advanced therapies to treat a range of devastating rare and orphan diseases.

Amicus Therapeutics (FRA:AM6) Headlines

No Headlines